EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer.

导出 OA

翻译打印收藏纠错

作者： Fabian,Falkenbach ^[1] ; Francesca,Ambrosini ^[1] ; Pierre,Tennstedt ^[2] ; Matthias,Eiber ^[1] ; Matthias M,Heck ^[3] ; Felix,Preisser ^[3] ; Markus,Graefen ^[1] ; Lars,Budäus ^[1] ; Daniel,Koehler ^[1] ; Sophie,Knipper ^[4] ; Tobias,Maurer ^[1]

作者单位： Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. ^[1] IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy. ^[2] Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, 81675 Munich, Germany. ^[3] Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. ^[4] Department of Urology, Vivantes Klinikum am Urban, 10967 Berlin, Germany. ^[5] Department of Urology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. ^[6]

关键词 PSA doubling time PSA kinetics PSA velocity PSMA hormone-sensitive metastasis-directed therapy oligorecurrent prostate cancer positron emission tomography radioguided surgery

DOI 10.3390/cancers15205008

PMID 37894375

发布时间 2023-10-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交